-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
The China Association of Chemical Pharmaceutical Industry Leads an Environmental Protection Expert Group to Conduct a Research Visit to Guangxiang Pharmaceutical, Shijiazhuang No.4 Pharmaceutical Group
Category:
TIME：2025-07-11
On July 8, Pan Guangcheng, Senior President of the China Association for Pharmaceutical Industry, led a research delegation comprising experts from the Engineering Technology Center for Harmless Treatment and Resource Utilization of Antibiotic Fermentation Residues under the Ministry of Ecology and Environment, the Chinese Academy of Environmental Sciences, Harbin Institute of Technology (Shenzhen), and other institutions, to conduct a focused field study at Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group. The visit centered on the topics of harmless treatment of antibiotic fermentation residues, prevention and control of emerging pollutants, and the development of environmental protection technical specifications and standards. Wu Hengyao, President of the Group; Shi Jianhui, Secretary of the Party Committee and Executive President; Cui Yongbin, Chairman of Guangxiang Pharmaceutical; and Zhang Zanyuan, General Manager, accompanied the delegation throughout the visit.
During the field visit, the research team toured the company’s exhibition hall, central control room, production facilities, and environmental protection workshops, conducting on-site inspections of key operational aspects such as corporate development and production processes, wastewater treatment systems, and exhaust gas treatment systems. Pan Guangcheng commended the Group for accelerating its integrated “API-plus-formulation” development model, particularly recognizing the remarkable achievements made by Guangxiang Pharmaceutical over the seven years since it began operations in areas such as technological innovation, the implementation of green pharmaceutical principles, and international business expansion.
During the symposium and exchange, the research team’s experts engaged in in-depth and detailed discussions with relevant executives from the Group and Guangxiang Pharmaceutical on a range of research topics, including trends in the API industry, the application of cutting-edge environmental protection technologies, the harmless treatment of microbial residue, the pretreatment of high-concentration wastewater, and the development of policies, regulations, and standards for the control of emerging pollutants.
Pan Guangcheng emphasized that this research initiative is a crucial step in implementing the national action plan for the control of emerging pollutants. The association will integrate industry–university–research resources to advance the development and refinement of the group standard “Technical Specifications for the Harmless Treatment of Antibiotic-Producing Microbial Residue,” promote the establishment of green production systems by enterprises, facilitate the transition from “reactive response” to “proactive governance,” and support the formulation and implementation of the 15th Five-Year Plan.
During the symposium, Wu Hengyao stated that the company has consistently prioritized environmental protection and actively embraced the concept of green development. Moving forward, the company will collaborate with the research team to provide foundational data, further deepen cooperation with relevant engineering centers and research institutes, and explore advanced pre-treatment technologies for high-concentration wastewater, air pollution control, and the resource utilization of microbial sludge. By leveraging technological innovation to enhance environmental performance, the company aims to continuously strengthen its competitive edge.
The Group’s and Guangxiang Pharmaceutical’s environmental protection officers attended the research visit and put forward suggestions on antibiotic detection in aquatic environments and the establishment of technical standards for emerging pollutants.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
